Case report: Extreme levels of serum S-100B in a patient with chronic subdural hematoma

Frontiers in Neurology

Volumn 3 DEC, Issue , 2012, Pages

  Persson, Malin Elisabet ^a   PeterThelin, Eric ^b   Bellander, Bo Michael ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Biomarkers; Human; Malignant melanoma; Neurosurgery; S 100b

Indexed keywords

MELAN A; MIDAZOLAM; MORPHINE; PROPOFOL; PROTEIN S100B;

ADULT; ARTICLE; AUTOPSY; BRAIN DECOMPRESSION; BRAIN HERNIA; BRAIN METASTASIS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DEEP SEDATION; FLUID THERAPY; GLASGOW COMA SCALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INDUCED HYPOTHERMIA; INTRACRANIAL PRESSURE; INTRAOPERATIVE PERIOD; KIDNEY METASTASIS; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MELANOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PLEURA METASTASIS; PROTEIN BLOOD LEVEL; SUBDURAL HEMATOMA; SURGICAL DRAINAGE; UNCONSCIOUSNESS;

EID: 84874574428     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2012.00170     Document Type: Article

References (30)

1. Anderson,R. E., Hansson,L. O., Nilsson, O., Dijlai-Merzoug, R., and Setter-gren, G. (2001). High serum S100B levels for trauma patients without head injuries. Neurosurgery 48, 1255-1258; discussion 1258-1260.
2. Bellander,B. M., Olafsson,I.H., Ghatan, P. H., Bro Skejo, H. P., Hansson, L. O., Wanecek, M., et al. (2011). Secondary insults following traumatic brain injury enhance complement activation in the human brain and release of the tissue damage marker S100B. Acta Neurochir. (Wien) 153, 90-100.
3. Egberts, F., Hitschler, W. N., Weichen-thal, M., and Hauschild, A. (2009). Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse. Melanoma Res. 19, 31-35.
4. Foerch, C., Otto, B., Singer, O. C., Neumann-Haefelin, T., Yan, B., Berkefeld, J., et al. (2004). Serum S100B predicts a malignant course of infarction in patients with acute middle cerebral artery occlusion. Stroke 35, 2160-2164.
5. Ghanem, G., Loir, B., Morandini, R., Sales, F., Lienard, D., Eggermont, A., et al. (2001). On the release and half-life of S100B protein in the peripheral bloodof melanoma patients.Int. J. Cancer 94, 586-590.
6. Hayakata, T., Shiozaki, T., Tasaki, O., Ikegawa, H., Inoue, Y., Toshiyuki, F., et al. (2004). Changes in CSF S100B and cytokine concentrations in early-phase severe traumatic brain injury. Shock 22, 102-107.
7. Herrmann, M., Curio, N., Jost, S., Gru-bich, C., Ebert, A. D., Fork, M. L., et al. (2001). Release of biochemical markers of damage to neuronal and glial brain tissue is associated with short and long term neuropsy-chological outcome after traumatic brain injury. J. Neurol. Neurosurg. Psychiatr. 70, 95-100.
8. Herrmann, M., Curio, N., Jost, S., Wun-derlich, M. T., Synowitz, H., and Wallesch, C. W. (1999). Protein S-100B and neuron specific enolase as early neurobiochemical markers of the severity of traumatic brain injury. Restor. Neurol. Neurosci. 14, 109-114.
9. Jonsson, H., Johnsson, P., Birch-Iensen, M., Alling, C., Westaby, S., and Blomquist,S. (2001). S100B as a predictor of size and outcome of stroke after cardiac surgery. Ann. Thorac. Surg. 71, 1433-1437.
10. Jonsson, H., Johnsson, P., Hoglund, P., Alling, C., and Blomquist, S. (2000). Elimination of S100B and renal function after cardiac surgery. J. Car-diothorac. Vasc. Anesth. 14, 698-701.
11. Kapural, M., Krizanac-Bengez, L., Bar-nett, G., Perl, J., Masaryk, T., Apollo, D., et al. (2002). Serum S-100beta as a possible marker of blood-brain barrier disruption. Brain Res. 940, 102-104.
12. Kleine, T. O., Benes, L., and Zofel, P. (2003). Studies of the brain specificity of S100B and neuron-specific enolase (NSE) in blood serum of acute care patients. Brain Res. Bull. 61, 265-279.
13. Korfias, S., Stranjalis, G., Boviatsis, E., Psachoulia, C., Jullien, G., Gregson, B., et al. (2007). Serum S-100B protein monitoring in patients with severe traumatic brain injury. Intensive Care Med. 33, 255-260.
14. Korfias, S., Stranjalis, G., Psachoulia, C., Vasiliadis, C., Pitaridis, M., Boviatsis, E., et al. (2006). Slight and short-lasting increase of serum S-100B protein in extra-cranial trauma. Brain Inj. 20, 867-872.
15. Lins, H., Wallesch, C. W., and Wunder-lich, M. T. (2005). Sequential analyses of neurobiochemical markers of cerebral damage in cerebrospinal fluid and serum in CNS infections. Acta Neurol. Scand. 112, 303-308.
16. Martenson, E. D., Hansson, L. O., Nils-son, B., Von Schoultz, E., Mans-son Brahme, E., Ringborg, U., et al. (2001). Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma. J. Clin. Oncol. 19, 824-831.
17. Moore, B. W. (1982). Chemistry and biology of the S-100 protein. Scand. J. Immunol. Suppl. 9, 53-74.
18. Oertel, M., Schumacher, U., Mcarthur, D. L., Kastner, S., and Boker, D. K. (2006). S-100B and NSE: markers of initial impact of subarachnoid haemorrhage and their relation to vasospasm and outcome. J. Clin. Neurosci. 13, 834-840.
19. Olivecrona, M., Rodling-Wahlstrom, M., Naredi, S., and Koskinen, L. O. (2009). S-100B and neuron specific enolase are poor outcome predictors in severe traumatic brain injury treated by an intracranial pressure targeted therapy. J. Neurol. Neuro-surg. Psychiatr. 80, 1241-1247.
20. Pelinka, L. E., Toegel, E., Mauritz, W., and Redl, H. (2003). Serum S 100 B: a marker of brain damage in traumatic brain injury with and without multiple trauma. Shock 19, 195-200.
21. Pham, N., Fazio, V., Cucullo, L., Teng, Q., Biberthaler, P., Bazar-ian, J. J., et al. (2010). Extracra-nial sources of S100B do not affect serum levels. PLoS ONE 5:e12691. doi:10.1371/journal.pone.0012691
22. Raabe, A., Kopetsch, O., Woszczyk, A., Lang, J., Gerlach, R., Zimmermann, M., et al. (2004). S-100B protein as a serum marker of secondary neurological complications in neurocrit-ical care patients. Neurol. Res. 26, 440-445.
23. Savola, O., Pyhtinen, J., Leino, T. K., Siitonen, S., Niemela, O., and Hill-bom, M. (2004). Effects of head and extracranial injuries on serum protein S100B levels in trauma patients. J. Trauma.56,1229-1234; discussion 1234.
24. Smit, L. H., Nieweg, O. E., Mooi, W. J., Bonfrer, J. M., Haanen, J. B., Kroon, B. B., et al. (2008). Value of serum S-100B for prediction of distant relapse and survival in stage III B/C melanoma. Anticancer Res. 28, 2297-2302.
25. Stalnacke, B. M., Ohlsson, A., Tegner, Y., and Sojka, P. (2006). Serum concentrations of two biochemical markers of brain tissue damage S-100B and neurone specific enolase are increased in elite female soccer players after a competitive game. Br. J. Sports Med. 40, 313-316.
26. Steiner, J., Bernstein, H. G., Bielau, H., Berndt, A., Brisch, R., Mawrin, C., et al. (2007). Evidence for a wide extra-astrocytic distribution of S100B in human brain. BMC Neurosci. 8:2. doi:10.1186/1471-2202-8-2
27. Studahl, M., Gunther, G., and Rosen-gren, L. (2009). Serum S-100B protein levels in patients with herpes simplex encephalitis and tick-borne encephalitis-amarkerof CNS damage during the initial stage of disease. J. Neurol. 256, 586-590.
28. Tibbling, G., Link, H., and Ohman, S. (1977). Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand. J. Clin. Lab. Invest. 37, 385-390.
29. Woertgen, C., Albert, R., Kohler, M., Rzepecki, A., Rothoerl, R. D., Bein, T., et al. (2004). Ventricular tapping seems to have no influence on S-100B and NSE serum concentrations. Neurosurg. Rev. 27, 178-180.
30. Woertgen, C., Rothoerl, R. D., Holzschuh, M., Metz, C., and Brawanski, A. (1997). Comparison of serial S-100 and NSE serum measurements after severe head injury. Acta Neurochir. (Wien) 139, 1161-1164; discussion 1165.